Tag Archives: drugs

National Clean Out Your Medicine Cabinet Day

Posted on by MaryO

This is a holiday I can really get behind!

Gear up for National Clean Out Your Medicine Cabinet Day! Happening every third Friday in April, this crucial day is all about purging your home of unused or expired medications that could pose serious risks.

Why should you care? Leftover medications can tempt family members, friends, or visitors, potentially leading to misuse or abuse. Plus, improper disposal can wreak havoc on our environment, contaminating the water we drink and the soil that nourishes our food.

How to Make a Difference:

1. **Survey and Sort:** Dive into every nook where medications might hide — from medicine cabinets to kitchen drawers. Don’t forget to check your pet’s meds too!

2. **Eco-Friendly Disposal:** Say no to flushing meds! Opt for at-home drug disposal solutions like DisposeRx to keep our waters clean.

3. **DEA National Drug Takeback Day:** Got a stash to clear out? Join in on DEA’s Takeback Day, held twice a year for those larger hauls.

Share Your Success: After you’ve cleared out your meds, snap a photo and share it on social using the hashtag #CleanOutMedsDay. Let’s spread the word and encourage others to join the movement!

DisposeRx initiated National Clean Out Your Medicine Cabinet Day in 2019 to spotlight the dangers of hoarding old meds. With risks ranging from drug addiction to accidental poisoning, it’s more important than ever to keep our homes safe and our environments clean.

Mark your calendars! This day is officially recognized on the third Friday in April each year. And remember, when it comes to medicine, storage matters. Keep your meds in cool, dry, dark places to preserve their potency.

Did you know? Medications can lose or even increase their potency over time, depending on how they’re stored. Make sure your meds are safe and effective by keeping them in optimal conditions.

Join in making homes safer and the planet healthier on National Clean Out Your Medicine Cabinet Day!

 

Exelixis’ Kidney Cancer Drug Cabometyx Positive in Phase II

Posted on by MaryO

Exelixis, Inc. (EXEL – Analyst Report) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).

Results showed that Cabometyx led to significant improvement in progression-free survival in patients with previously untreated advanced RCC, compared with sunitinib. Consequently, the trial met its primary endpoint.

Safety data from the Cabometyx arm of the study were consistent with those observed in previous studies in patients with advanced RCC.

Final results of the trial will be presented at a medical conference shortly.

We remind investors that Cabometyx (the tablet formulation of cabozantinib) was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC, who have received prior anti-angiogenic therapy.

Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Exelixis’ partner, Ipsen. The MAA has been granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates a review period of 150 days instead of the standard 210 days.

Exelixis also plans to submit results of the CABOSUN trial to regulatory authorities in order to discuss further development of Cabometyx and submission strategy for the treatment of first-line advanced RCC.

As per the American Cancer Society, kidney cancer is one of the top 10 most commonly diagnosed forms of cancer in both men and women in the U.S. Hence, approval of Cabometyx in first-line advanced RCC will boost its growth prospects significantly.

Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Abbott Laboratories (ABT – Analyst Report) , Johnson & Johnson (JNJ – Analyst Report) and Sanofi (SNY – Analyst Report) . All three stocks carry a Zacks Rank #2 (Buy).

From https://www.zacks.com/stock/news/218403/exelixis-kidney-cancer-drug-cabometyx-positive-in-phase-ii

Heart Attacks and Depression

Posted on by MaryO

Studies show that 48 percent of people can develop depression following a heart attack. But experts say this depression may not be purely psychological. After a cardiac event, the heart may be unable to pump blood as efficiently—causing patients to lose energy.

In addition, chemicals are released in the brain that can work to physiologically cause mood changes. Interestingly, the same study showed that women who suffer heart attacks are 20 percent more likely to develop depression.

The good news: most of these cases can be treated with anti-depressant drugs.